Table 4.
Pathologic evaluation of breast tumors before and after neoadjuvant chemotherapy (n, column %).
| Pathologic comparison | Before NAC n (%) | After NAC n (%) | p |
|---|---|---|---|
| Tumor pathology | (via tru-cut bx. of the breast) | ||
| No tumor | 0 (0.0) | 23 (25.0) | |
| DCIS | 0 (0.0) | 3 (3.3) | NA |
| Infiltrating ductal carcinoma (IDC) | 87 (94.6) | 60 (65.2) | |
| Infiltrating lobular carcinoma (ILC) | 3 (3.3) | 2 (2.2) | |
| Other | 2 (2.2) | 4 (4.3) | |
|
| |||
| ER | McNemar p= | ||
| Negative | 22 (23.9) | 12 (13.0) | |
| Positive | 66 (71.7) | 57(62.0) | |
| Unavailable | 4 (4.3) | 23 (25.0) | |
| Mean (%) ± SD | 76.53 ± 21.85 | 80.57 ± 23.99 | Mean p=0.034 |
|
| |||
| PR | McNemar p= | ||
| Negative | 25 (27.2) | 20 (21.7) | |
| Positive | 64 (69.6) | 48 (52.2) | |
| Unavailable | 3 (3.3) | 24 (26.1) | |
| Mean (%) ± SD | 63.05 ± 32.40 | 55.05 ± 31.87 | Mean p=0.098 |
|
| |||
| CerbB2 | |||
| Negative | 63 (68.5) | 51 (55.4) | McNemar p= |
| Positive | 29 (31.5) | 16 (17.4) | |
| Unavailable | 0 (0) | 25 (27.2) | |
|
| |||
| Ki67 | |||
| Mean (%) ± SD | 25.75 ± 15.16 | 20.36 ± 13.68 | 0.024 |
|
| |||
| P53 | |||
| Mean (%) ± SD | 35.83 ± 38.27 | 37.50 ± 39.12 | <0.001 |
|
| |||
| Histologic grade | |||
| 1 | 5 (5.4) | ||
| 2 | 37 (40.2) | ||
| 3 | 16 (17.4) | ||
|
| |||
| Nuclear grade | |||
| 1 | 3 (3.3) | ||
| 2 | 28 (30.4) | ||
| 3 | 25 (27.2) | ||
|
| |||
| Lymphovascular invasion | |||
| Absent | 58 (63) | ||
| Present | 11 (12) | ||